Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries
Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries have?
Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries has 0 citations in the OpenAlex counts ScholarIQ stores.
When was Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries published?
Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries has 2017 year in the ScholarIQ index.
What is the open-access status of Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries?
Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries has closed oa status in the ScholarIQ index.
What is the DOI of Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries?
The DOI for Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries is on the source record.
What is the OpenAlex record for Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries?
The OpenAlex for Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries is on the source record.